welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
In a Select Group of Patients Meeting Strict Clinical Criteria and Undergoing Ileal Pouch-Anal Anastomosis, the Omis...PURPOSE : Ileal pouch-anal anastomosis i...
-
Bonnies Diary April 08https://jtvcancersupport.com/embed/46253...
-
Studies of the Foregut in Patients with Familial Adenomatous Polyposis (FAP): The Clinical Problem, Management, and ...Thirty-eight published papers, co-author...
-
Special Concerns for People with J-PouchesAfter having an ileoanal reservoir proce...
-
Colorectal Cancer in Familial Adenomatous Polyposis: Are there Clinical Predictive Factors?BACKGROUND : Familial Adenomatous Polypo...
-
Our Experience of Treatment of Cribriform Morular Variant of Papillary Thyroid Carcinoma; Difference in Clinicopatho...Cribriform-morular variant (CMV) is a co...
-
Inherited Colorectal Cancer Syndromes – Diagnosis and ManagemntColorectal cancer is the most common gas...